1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
RFA-AG-25-016: Multi-Scale Computational Models of Aging and Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) is sponsored by National Institute on Aging (NIA). This funding opportunity invites applications for multi-scale computational models that recapitulate dynamic changes associated with aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).
The scope includes various computational approaches such as mathematical and computational modeling, image analysis, artificial intelligence, and machine learning to understand aging processes and AD/ADRD across molecules, cells and networks, and cognition and behavior.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants include Public and State controlled institutions of higher education, Private institutions of higher education, and other entities. Confirm the full requirements in the official notice before applying.
RFA-AG-25-016: Multi-Scale Computational Models of Aging and Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article